Dr. Jones retired from Eli Lilly and Company at the end of 2018 as Chief Scientific Officer-Toxicology and Pathology. He continues to utilize his experience and insights regarding the performance of nonclinical safety testing as Manger and Founder of Safety First Consulting, LLC. He also holds an appointment as Adjunct Associate Professor of Medicine in the Division of Clinical Pharmacology at Indiana University School of Medicine.Dr. Jones received his Ph.D. in Experimental Pathology from the University of Maryland under the guidance of Dr. Benjamin F. Trump and completed a post-doctoral fellowship with Dr. Sten Orrenius at the Karolinska Institute in Stockholm, Sweden. He joined the faculty of the University of Maryland School of Medicine in the Department of Pathology and rose to the rank of Associate Professor with tenure. His laboratory received major funding support from the American Cancer Society and the National Institutes of Health. Dr. Jones joined Eli Lilly and Co. in 1991 as a Research Scientist in Toxicology. His nearly 28-year career included a variety of technical and administrative roles. From 2009 until his retirement, Dr. Jones was responsible for providing scientific oversight and administrative leadership for the Toxicology and Pathology organization and oversaw the nonclinical safety support for the entire Lilly Research Laboratories (LRL) portfolio. He served on several key LRL Committees responsible for portfolio management and patient safety.Dr. Jones has been an active member of the Society of Toxicology for over 30 years. He was the Lilly representative to the Preclinical Safety Leadership Group (DruSafe) within the International Consortium for Innovation and Quality in Pharmaceutical Development and served on the Coordinating Committee from 2013 to 2015. He was also a founding member of the BioCelerate/TransCelerate Toxicology Data Sharing Project attempting the first sustainable cross-industry toxicology data sharing initiative using SEND data. He also served over 8 years as the nonclinical safety representative for the Development Special Emphasis Panel supporting the NCI Experimental Therapeutics (NExT) Program. Through his accumulated experiences, Dr. Jones has developed valuable insights into the challenges and opportunities associated with the application of nonclinical safety data in human risk management.